MPT Stock Analysis: Medical Properties Trust | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 2.890m USD | 12M Return: 23.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.1M
Qual. Beats: 0
Rev. Trend: -28.0%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medical Properties Trust, Inc. (NYSE: MPT) is a self-advised real estate investment trust (REIT) focused on acquiring and developing net-leased hospital facilities. The company, which was incorporated in 2003 and went public in 2005, is headquartered in Birmingham, Alabama and operates as one of the worlds largest owners of hospital real estate, with 388 facilities and approximately 39,000 licensed beds across nine countries and three continents as of September 30, 2025.
MPTs financing model is designed to help hospital operators unlock the value of their real estate assets, enabling them to fund facility improvements, technology upgrades, and other operational investments. Under its net-lease structure, tenants are typically responsible for property-level expenses such as taxes, insurance, and maintenance, which is a common arrangement within the healthcare REIT sub-industry. REITs like MPT are generally required to distribute a substantial portion of their taxable income to shareholders in the form of dividends, a structural feature that can make them sensitive to interest rate movements.
Classified within the GICS Real Estate sector and the Health Care REITs sub-industry, MPT is positioned as a mid-cap stock with a market capitalization of approximately $2.6 billion USD. The company differentiates itself from broader diversified REITs by concentrating exclusively on hospital and acute care properties, a niche segment that ties its performance closely to the financial health of hospital operators and the broader healthcare delivery system.
- Steward Health Care defaults drive tenant credit losses
- Dividend cut undermines REIT income investor appeal
- UK NHS funding pressures threaten European hospital rents
- Asset sale program accelerates to reduce leverage ratio
| Net Income: -125.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.31 > 1.0 |
| NWC/Revenue: 14.06% < 20% (prev 48.68%; Δ -34.62% < -1%) |
| CFO/TA 0.01 > 3% & CFO 216.1m > Net Income -125.9m |
| Net Debt (9.44b) to EBITDA (946.9m): 9.97 < 3 |
| Current Ratio: 1.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (597.7m) vs 12m ago -0.48% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 6.75% > 50% (prev 6.41%; Δ 0.35% > 0%) |
| Interest Coverage Ratio: 1.04 > 6 (EBIT TTM 666.2m / Interest Expense TTM 641.0m) |
| A: 0.01 (Total Current Assets 1.35b - Total Current Liabilities 1.21b) / Total Assets 14.8b |
| B: -0.28 (Retained Earnings -4.16b / Total Assets 14.8b) |
| C: 0.04 (EBIT TTM 666.2m / Avg Total Assets 14.8b) |
| D: 0.44 (Book Value of Equity 4.54b / Total Liabilities 10.2b) |
| Altman-Z'' = -0.09 = B |
| DSRI: 0.96 (Receivables 922.1m/909.6m, Revenue 1.00b/951.5m) |
| GMI: 1.01 (GM 96.90% / 96.07%) |
| AQI: 1.11 (AQ_t 0.16 / AQ_t-1 0.14) |
| SGI: 1.05 (Revenue 1.00b / 951.5m) |
| TATA: -0.02 (NI -125.9m - CFO 216.1m) / TA 14.8b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 18, 2026, the stock is trading at USD 4.75 with a total of 3,377,534 shares traded. Over the past week, the price has changed by +5.32%, over one month by +2.15%, over three months by -7.42% and over the past year by +23.55%.
Current recommended Stop Loss: 4.50 (which is 5.3% or 1.7 ATR below the current price).
Medical Properties Trust has no consensus analysts rating.
P/E Forward = 6.6667
P/S = 2.6277
P/B = 0.6343
P/EG = 1.6083
Revenue TTM = 1.00b USD
EBIT TTM = 666.2m USD
EBITDA TTM = 946.9m USD
Long Term Debt = 9.00b USD (from longTermDebt, last quarter)
Short Term Debt = 102.5m USD (from shortTermDebt, last quarter)
Debt = 9.87b USD (from shortLongTermDebtTotal, last quarter) + Leases 102.5m
Net Debt = 9.44b USD (calculated: Debt 9.87b - CCE 425.0m)
Enterprise Value = 12.3b USD (2.89b + Debt 9.87b - CCE 425.0m)
Interest Coverage Ratio = 1.04 (Ebit TTM 666.2m / Interest Expense TTM 641.0m)
EV/FCF = 57.06x (Enterprise Value 12.3b / FCF TTM 216.1m)
FCF Yield = 1.75% (FCF TTM 216.1m / Enterprise Value 12.3b)
FCF Margin = 21.61% (FCF TTM 216.1m / Revenue TTM 1.00b)
Net Margin = -12.59% (Net Income TTM -125.9m / Revenue TTM 1.00b)
Gross Margin = unknown ((Revenue TTM 1.00b - Cost of Revenue TTM 39.3m) / Revenue TTM)
Tobins Q-Ratio = 0.84 (Enterprise Value 12.3b / Total Assets 14.8b)
Interest Expense / Debt = 6.50% (Interest Expense 641.0m / Debt 9.87b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 526.3m (EBIT 666.2m * (1 - 21.00%))
Current Ratio = 1.12 (Total Current Assets 1.35b / Total Current Liabilities 1.21b)
Debt / Equity = 2.17 (Debt 9.87b / totalStockholderEquity, last quarter 4.54b)
Debt / EBITDA = 9.97 (Net Debt 9.44b / EBITDA 946.9m)
Debt / FCF = 43.69 (Net Debt 9.44b / FCF TTM 216.1m)
Total Stockholder Equity = 4.66b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.85% (Net Income -125.9m / Total Assets 14.8b)
RoE = -2.70% (Net Income TTM -125.9m / Total Stockholder Equity 4.66b)
RoCE = 4.88% (EBIT 666.2m / Capital Employed (Equity 4.66b + L.T.Debt 9.00b))
RoIC = 3.58% (NOPAT 526.3m / Invested Capital 14.7b)
WACC = 5.64% (E(2.89b)/V(12.8b) * Re(7.37%) + D(9.87b)/V(12.8b) * Rd(6.50%) * (1-Tc(0.21)))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -1.89 | Cagr: -0.09%
[DCF] Terminal Value 77.97% ; FCFF base≈198.3m ; Y1≈227.3m ; Y5≈334.5m
[DCF] Fair Price = N/A (negative equity: EV 5.03b - Net Debt 9.44b = -4.41b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.42 | # QB: 0
Revenue Correlation: -27.99 | Revenue CAGR: -7.03% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.11 | Chg30d=+37.50% | Revisions=-25% | GrowthEPS=+0.0% | GrowthRev=+6.5%
EPS next Year (2027-12-31): EPS=0.15 | Chg30d=-11.09% | Revisions=+0% | GrowthEPS=+33.3% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -17% (up=1, down=2)